COMPANY PROFILE

OVERVIEW

Company
Rhelixa, Inc.
Office / Lab
5F KDX Ginza East Bldg., 3-7-2, Chuo-ku, Irifune, Tokyo, Japan.
Foundation
Feb. 2015
business
Omics research and consulting services
Development and operation of cloud-based services
Certification
JIS Q 27001:2014(ISO/IEC 27001:2013) MSA-IS-612
PARTNER








BUSINESS DATAas of Mar. 2023
Company
188company
Institute
275institute
Project
5348 project
MEMBER
MANAGEMENT

Representative Director, CEO/CTO (Founder)
Ryo Nakaki
Ryo Nakaki holds a Ph.D. in Engineering from Department of Genome Science, Research Center for Advanced Science and Technology, Tokyo University. Ryo specializes in the analysis of large-scale omics data, especially epigenomic analysis. Ryo is a councilor of the Japanese Society of Anti-Aging Medicine.

Director, CSO
Tomoyuki Matsuno
After graduating from Yokohama National University, Tomoyuki joined Mitsubishi Corporation, where he was in charge of global sales and trading of derivatives products. Then worked for a U.S. trading company before becoming CEO of Rhelixa.

Director, CFO
Ryota Kamiya
After graduating from Yokohama National University, Ryota joined Nippon Life Insurance Company, where he was engaged in corporate planning and management of group companies in the Asset Management Division. After joining Rhelixa,He reformed the company's internal systems and management infrastructure to take the company public.
ADVISER

Yukihiro Maru (Ph.D.)
Established Leave a Nest Co., Ltd. in 2002. Engaged in the "knowledge production industry," creating new businesses by combining technologies and knowledge from various fields. Building one of the largest deep tech ecosystems in Asia, and working on solving global-scale challenges. Involved in the launch of numerous deep tech ventures, including Euglena Co., Ltd.

Hidekazu Yamada(MD.,PhD.)
Yasuharu Kanki (M.D., Ph.D.)
Graduated from Kyoto University School of Medicine (M.D.). Obtained a Ph.D. from the Laboratory for Systems Biology and Medicine (LSBM) at the University of Tokyo's Research Center for Advanced Science and Technology. Has experience studying at the National Institutes of Health (NIH). Has numerous research publications on vascular epigenomics.
Co-authored Papers
G3 (Bethesda). 2022 Jul 1:jkac166. doi: 10.1093/g3journal/jkac166. Online ahead of print.
Nat Commun. 2021 Dec 2;12(1):7045. doi: 10.1038/s41467-021-27321-5.
Sci Rep. 2021 Sep 21;11(1):18687. doi: 10.1038/s41598-021-98344-7.
Sci Signal. 2021 Jan 26;14(667):eabb3616. doi: 10.1126/scisignal.abb3616.
EMBO J. 2020 Mar e103949. doi.org/10.15252/embj.2019103949
Cell Rep. 2019 Oct 1;29(1):162-175.e9. doi: 10.1016/j.celrep.2019.08.086.
G3 (Bethesda). 2022 Jul 1:jkac166. doi: 10.1093/g3journal/jkac166. Online ahead of print.
Nat Commun. 2021 Dec 2;12(1):7045. doi: 10.1038/s41467-021-27321-5.
Sci Rep. 2021 Sep 21;11(1):18687. doi: 10.1038/s41598-021-98344-7.
Sci Signal. 2021 Jan 26;14(667):eabb3616. doi: 10.1126/scisignal.abb3616.
EMBO J. 2020 Mar e103949. doi.org/10.15252/embj.2019103949
Cell Rep. 2019 Oct 1;29(1):162-175.e9. doi: 10.1016/j.celrep.2019.08.086.
Epigenetics & Chromatin 12, 77 (2019). doi.org/10.1186/s13072-019-0319-0
EMBO Rep. 2018 Dec;19(12):e46255. doi:10.15252/embr.201846255
EMBO J. 2018 Jul 2;37(13). pii: e97723. doi: 10.15252/embj.201797723.
Nat Commun. 2018 Apr 19;9(1):1566. doi: 10.1038/s41467-018-03868-8.
Sci Rep. 2018 Feb 28;8(1):3779. doi: 10.1038/s41598-018-22180-5.
Nat Cell Biol. 2017 Sep;19(9):1081-1092. doi: 10.1038/ncb3590.
Nucleic Acids Res. 2017 May 5;45(8):4344-4358. doi: 10.1093/nar/gkx159.
Cell Rep. 2017 Feb 28;18(9):2228-2242. doi: 10.1016/j.celrep.2017.02.006.
Mol Cell. 2015 Nov 19;60(4):584-96. doi: 10.1016/j.molcel.2015.10.025.
Nat Commun. 2015 May 7;6:7052. doi: 10.1038/ncomms8052.